Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data
Authors:
- Lourdes GutiérrezLGLourdes Gutiérrez
- Ana RoyuelaARAna Royuela
- Enric CarcerenyECEnric Carcereny
- Rafael López-CastroRLRafael López-Castro
- Delvys Rodríguez-AbreuDRDelvys Rodríguez-Abreu
- Bartomeu MassutiBMBartomeu Massuti
- José Luis González-LarribaJGJosé Luis González-Larriba
- Rosario García-CampeloRGRosario García-Campelo
- Joaquim Bosch-BarreraJoaquim Bosch-Barrera
- María GuiradoMGMaría Guirado
- Carlos CampsCCCarlos Camps
- Manuel DómineMDManuel Dómine
Open Access
- 30 August 2021
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-11
Abstract
There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist clinicians to predict survival beyond 24 months. EGFR mutated stage IIIB and IV NSCLC patients diagnosed between January 2009 and December 2017 included in the Spanish Lung Cancer Group (SLCG) thoracic tumor registry. Long-term survival was defined as being alive 24 months after diagnosis. A multivariable prognostic model was carried out using binary logistic regression and internal validation through bootstrapping. A nomogram was developed to facilitate the interpretation and applicability of the model. 505 of the 961 EGFR mutated patients identified in the registry were included, with a median survival of 27.73 months. Factors associated with overall survival longer than 24 months were: being a woman (OR 1.78); absence of the exon 20 insertion mutation (OR 2.77); functional status (ECOG 0–1) (OR 4.92); absence of central nervous system metastases (OR 2.22), absence of liver metastases (OR 1.90) or adrenal involvement (OR 2.35) and low number of metastatic sites (OR 1.22). The model had a good internal validation with a calibration slope equal to 0.781 and discrimination (optimism corrected C-index 0.680). Survival greater than 24 months can be predicted from six pre-treatment clinicopathological variables. The model has a good discrimination ability. We hypothesized that this model could help the selection of the best treatment sequence in EGFR mutation NSCLC patients.Keywords
This publication has 34 references indexed in Scilit:
- Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancersLung Cancer, 2015
- Common EGFR -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase InhibitorsFuture Oncology, 2015
- Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase InhibitorsCancer Research and Treatment, 2014
- Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patientsLung Cancer, 2013
- Effectiveness and response predictive factors of erlotinib in a non-small cell lung cancer unselected European population previously treated: A retrospective, observational, multicentric studyJournal of Oncology Pharmacy Practice, 2012
- Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerNew England Journal of Medicine, 2009
- A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21Journal of Thoracic Oncology, 2008
- How To Build and Interpret a Nomogram for Cancer PrognosisJournal of Clinical Oncology, 2008
- Biological and clinical implications of EGFR mutations in lung cancerInternational Journal of Clinical Oncology, 2006
- Measures of abstinence in clinical trials: issues and recommendationsNicotine & Tobacco Research, 2003